On November 11, 2021 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that a study published in Nature Medicine reinforces the benefits of using the Guardant360 liquid biopsy test to help guide treatment decisions for patients with HER2-driven metastatic colorectal cancer (mCRC) (Press release, Guardant Health, NOV 11, 2021, View Source [SID1234595292]). Led by the National Cancer Center Hospital East (NCCHE) in Japan, the study demonstrates that the Guardant360 test can select patients for HER2-directed therapy, identify which patients are responding to treatment, as well as identify genetic alterations that predict resistance.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase 2 TRastuzumab combIned with pertuzUMab for Patients with Her2-positive mCRC (TRIUMPH) study evaluated the efficacy of targeted therapy pertuzumab plus trastuzumab in patients with mCRC harboring HER2 amplification as detected by analysis of circulating tumor DNA (ctDNA) or tissue genotyping. All patients were previously treated with monoclonal antibodies targeting EGFR. Additional exploratory analyses were conducted to evaluate the utility of ctDNA genotyping to predict treatment efficacy, monitor response, and identify the resistance mechanisms.
The study, which follows on last year’s SCRUM-Japan GOZILA study, found that while efficacy of HER2-directed treatment was similar in patients with HER2 amplification detected in tissue or in ctDNA, the ctDNA analysis provided an added benefit of identifying additional alterations that predicted which patients would benefit from HER2-directed therapy. In addition, decreases in ctDNA shortly after treatment initiation corresponded with radiographic response and resistance-related alterations were identified by ctDNA genotyping after disease progression.
"This study demonstrates the clinical utility of the Guardant360 test in helping guide treatment decisions for patients with metastatic colorectal cancer," said Dr. Yoshiaki Nakamura, NCCHE, principal investigator of the TRIUMPH study. "Based on our results, we believe that ctDNA genotyping is beneficial in clinical practice to identify patients who are most likely to benefit from treatment with pertuzumab plus trastuzumab."
"Our Guardant360 blood test consistently demonstrates that it is a critical test in not only determining actionable biomarkers, but helping to guide treatment decisions," said Helmy Eltoukhy, Guardant Health Co-CEO. "This study reinforces the breadth and applicability of our Guardant360 test to help inform clinical decisions for patients with advanced cancer across their treatment journey."
The Guardant360 liquid biopsy test is part of the market leading Guardant360 portfolio that offers oncologists end-to-end testing solutions from treatment selection to treatment response monitoring. The portfolio includes the Guardant360 CDx test, the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid tumor cancers, and Guardant360 TissueNext to provide oncologists with another option for comprehensive genomic profiling. Also included is Guardant360 Response, the first blood-only liquid biopsy that enables oncologists to view molecular response, or changes in ctDNA levels, from a simple blood draw to get an early indication of whether a patient is responding to treatment. This tool assists oncologists when considering whether to continue, stop, or explore other treatment options for their patients with late-stage or metastatic cancer.
Since it was first introduced, the Guardant360 blood test has become widely accepted for blood-based comprehensive genomic profiling (CGP) with more than 250 peer-reviewed publications including over 60 clinical outcomes studies. It has been trusted by more than 9,000 oncologists with more than 150,000 tests performed to date.